<code id='6EB826B569'></code><style id='6EB826B569'></style>
    • <acronym id='6EB826B569'></acronym>
      <center id='6EB826B569'><center id='6EB826B569'><tfoot id='6EB826B569'></tfoot></center><abbr id='6EB826B569'><dir id='6EB826B569'><tfoot id='6EB826B569'></tfoot><noframes id='6EB826B569'>

    • <optgroup id='6EB826B569'><strike id='6EB826B569'><sup id='6EB826B569'></sup></strike><code id='6EB826B569'></code></optgroup>
        1. <b id='6EB826B569'><label id='6EB826B569'><select id='6EB826B569'><dt id='6EB826B569'><span id='6EB826B569'></span></dt></select></label></b><u id='6EB826B569'></u>
          <i id='6EB826B569'><strike id='6EB826B569'><tt id='6EB826B569'><pre id='6EB826B569'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:1
          The Federal Trade Commission office glows softly inside, contrasting with the darkness outside — coverage from STAT
          Adobe

          Over the past two decades, hundreds of hospital mergers have escaped federal antitrust scrutiny and led to both higher prices and less competition, a new study shows.

          But the study’s authors, and other researchers, believe the Federal Trade Commission’s hands often are tied. The agency simply doesn’t have enough money or people to crack down on all anticompetitive hospital deals, and some state laws shield hospital mergers from federal review completely.

          advertisement

          “The resources available are just not commensurate with what the agency needs,” said Zack Cooper, an associate professor of health policy and economics at Yale University and one of the co-authors of the study. “This isn’t a story of the FTC not knowing what to do. I actually think they really know, very clearly, what to do. It’s a lack of resources, person power, and potentially willingness to do it.”

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          Ventyx halts psoriasis drug development after lackluster trial results
          Ventyx halts psoriasis drug development after lackluster trial results

          AdobeSANDIEGO—VentyxBiosciencesreportedonMondaythatitwasendingdevelopmentofanexperimentaldrugfortrea

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Roche to buy Carmot Therapeutics, developer of obesity drugs

          SebastienBozon/AFPviaGettyImagesLONDON—Theboomingobesitymarketisattractinganotherplayer,aspharmagian